Stock listing

Neurizon Therapeutics Limited

Selected listing: A40STF · LSX · EUR · DE

Neurizon Therapeutics Limited (LS Exchange: A40STF), Health Technology. Latest release Oct 5, 2026: FDA Type C Feedback, HEALEY trial potentially registrational

A40STF:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A40STF
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

About Neurizon Therapeutics Limited

The company is focused on developing innovative therapeutic solutions. Neurizon aims to address unmet medical needs through its research and development efforts.

Latest news from Neurizon Therapeutics Limited

FDA Type C Feedback, HEALEY trial potentially registrational

October 5, 2026

Neurizon Announces Partial Redemption of Convertible Notes

September 9, 2026

NIH funds Expanded Access Program for NUZ-001 in ALS

September 8, 2026

Neurizon Appoints Chief Executive Officer

September 6, 2026

Appendix 4E and 2026 Annual Report

August 25, 2026

All Neurizon Therapeutics Limited news →

Research Neurizon Therapeutics Limited

Neurizon Therapeutics Limited company profile

View the public company page for Neurizon Therapeutics Limited on 6ix.

Neurizon Therapeutics Limited news

Read company news and market updates connected to Neurizon Therapeutics Limited.

Neurizon Therapeutics Limited investor events

Find investor webinars, events, and replay context for Neurizon Therapeutics Limited.